Common Cold — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for common cold. 20 active patents protecting 3 drugs from 3+ originators. First major cliff: 2032. Daily refresh.

3
Approved drugs
20
Active US patents
56/100
Avg vulnerability
—
Annual revenue covered

Originators in Common Cold

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Fresenius Kabi 14 patents Bayer 3 patents Generic (multiple manufacturers) 3 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating common cold. Each bar = one year. Y-axis scaled to peak year (9 patents).

1
27
9
32
7
34
3
35

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Dilaudid-Hp
Hydromorphone Hydrochloride
 Fresenius Kabi 14 46 — 2032-04-23
Tussionex Pennkinetic
CHLORPHENIRAMINE MALEATE
 Bayer 3 60 — 2027-02-28
Mucinex
guaifenesin
 Generic (multiple manufacturers) 3 62 — 2035-11-13

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
9066942 Tussionex Pennkinetic method of use 68 2032-01-03
7863287 Tussionex Pennkinetic formulation 65 2027-02-28
9808431 Mucinex method of use 62 2035-11-13
10105324 Mucinex method of use 62 2035-11-13
9549907 Mucinex method of use 62 2035-11-13
9731082 Dilaudid-Hp formulation 56 2032-04-23
9248229 Dilaudid-Hp formulation 50 2034-03-12
9107921 Tussionex Pennkinetic formulation 48 2032-01-03
9731082 Dilaudid-Hp formulation 48 2032-04-23
9731082 Dilaudid-Hp formulation 48 2032-04-23

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9248229 Dilaudid-Hp formulation 42 2034-03-12
9248229 Dilaudid-Hp formulation 42 2034-03-12
9248229 Dilaudid-Hp formulation 42 2034-03-12
9248229 Dilaudid-Hp formulation 42 2034-03-12
9248229 Dilaudid-Hp formulation 42 2034-03-12
9248229 Dilaudid-Hp formulation 42 2034-03-12
9731082 Dilaudid-Hp formulation 48 2032-04-23
9731082 Dilaudid-Hp formulation 48 2032-04-23
9731082 Dilaudid-Hp formulation 48 2032-04-23
9731082 Dilaudid-Hp formulation 48 2032-04-23

Related